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Abstract
L-3, 4-Dihydroxyphenylalanine (L-DOPA)-induced dyskinesia (LID) is a major clinical complication in the treatment of
Parkinson’s disease (PD). This debilitating side effect likely reflects aberrant compensatory responses for a combination
of dopaminergic neuron denervation and repeated L-DOPA administration. Abnormal endogenous opioid signal
transduction pathways in basal ganglia have been well documented in LID. Opioid receptors have been targeted to
alleviate the dyskinesia. However, the exact role of this altered opioid activity is remains under active investigation. In
the present review, we discuss the current understanding of opioid signal transduction in the basal ganglia and how
the malfunction of opioid signaling contributes to the pathophysiology of LID. Further study of the opioid system in
LID may lead to new therapeutic targets and improved treatment of PD patients.
Background
Parkinson’s disease (PD) is the most common degenera-
tive movement disorder clinically manifested with rest-
ing tremor, bradykinesia, rigidity and posture instability,
resulting from impairments of dopamine transmission in
the basal ganglia [1]. Pathologically, PD is marked by the
substantial degeneration of dopamine-producing neu-
rons in the substantia nigra pars compacta (SNc) and
the presence of intracellular protein aggregates named
Lewy bodies and neurites [2]. PD medications are mostly
targeted at symptom relief. Since its initial prescription
in 1960s, dopamine precursor L-DOPA remains the
most effective drug for treating the movement abnor-
malities [3]. However, from the very beginning, it has
been noticed that repeated administration of L-DOPA
can induce motor fluctuations as well as impulsive
control disorders [4]. Involuntary movements, also called
L-DOPA induced dyskinesia (LID), is the most disturb-
ing motor fluctuation. LID can be disabling and interfere
with daily living. On average, about half of the patients
develop LID after treated with L-DOPA for five years
[5]. Although intensive studies have been carried out to
understand the underlying molecular, cellular, and
circuit mechanisms of LID, there still lack agents that
can effectively ameliorate LID. Therefore, it remains
critical to develop novel therapeutic strategies to reduce
LID and improve the treatment and life quality of PD
patients.
Denervation of dopaminergic neurons and repeated L-
DOPA treatment might act together to cause LID [6].
The development of LID reflects multiplex compensa-
tory reactions of nervous system in response to innate
dopamine transmission deficiency and excessive supply
of L-DOPA as discussed comprehensively in a recent
review [7]. Here we paid special attention to the opioid
receptor-mediated neurotransmission. Endogenous opi-
oid peptides are dopamine co-transmitters that modulate
various neural transmissions in basal ganglia. Alterations
of opioid peptide expression and opioid receptor-
mediated intracellular signal transduction have been
reported in PD patients and animal models that develop
dyskinesia [8]. Targeting opioid signaling in the basal
ganglia may provide an additional avenue for the treat-
ment of LID in PD.
Endogenous opioid peptides and receptors
There are three families of endogenous opioid peptides and
three families of opioid receptors, comprising the so-called
endogenous opioid system in the brain [9]. Endogenous opi-
oid peptides consist of β-endorphin, enkephalins, and dynor-
phins, which are derived from precursor proteins encoded
by pre-proopiomelanocortin (POMC), preproenkephalin
(PENK), and pre-prodynorphin (PDYN), respectively [10].
Each precursor undergoes complex post-translational
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modifications and proteolytic cleavage, giving rise to mul-
tiple active peptides [11, 12]. For instance, PENK is the
precursor for two extended forms of Methionine (Met)-
enkephalin and a single form of Leucine (Leu)-enkephalin.
Opioid receptors can be divided into μ, δ, and κ three
families, encoded by OPRM, OPRD, and OPRK genes [4,
13, 14]. While they are all G protein–coupled receptors,
their extracellular loops are less conserved and responsible
for the differential binding affinities to different opioid
peptides [4, 13, 15–17]. All three subtypes of opioid recep-
tors are coupling with the downstream Gi or Go-mediated
inhibitory intracellular signaling transduction pathways
[18]. Furthermore, endogenous opioid peptides and recep-
tors exhibit uneven distribution in different brain regions
and cell types, and can act either pre- or post-synaptically.
Therefore, the opioid system exerts a variety of modula-
tory roles in multiple neural processes, including pain
sensation, reward and drug addiction, as well as seizure
and PD [11].
Functional organization of basal ganglia
Increasing evidence suggests that well-coordinated
direct and indirect striatal outputs in the basal ganglia
are essential for the proper motor control [19]. On the
other hand, a disruption of the coordination may
cause parkinsonian as well as dyskinetic states [20].
The dopamine receptor D1 (DRD1)-expressing striatal
projection neurons (dSPNs) form the direct pathway
and project to the globus pallidus internal segment
(GPi) as well as the substantia nigra pars reticulata
(SNr) and SNc, while the dopamine receptor D2
(DRD2)-expressing SPNs (iSPNs) make up the indirect
pathway and innervate the globus pallidus external
segment (GPe) and the subthalamic nucleus (STh),
where the GPe and STh neurons target their axons to
the SNr (Fig. 1) [19, 20]. The direct pathway is used to
be regarded as a promoter of movement, in opposite
to the indirect pathway that inhibits the motor activity
[19]. Along this line of thinking, PD weakens the dir-
ect pathway and potentiates the indirect pathway,
resulting in impairments of movement [19, 21]. How-
ever, the recent live imaging studies of SPNs in free
moving rodents argue against this binary “to go or not
to go” model, and suggest a concerted activity of dir-
ect and indirect pathway SPNs is essential for the
proper motor control in both moving and resting
states [22–24]. In addition, the latest neuron tracing
studies reveal a much more complicated and diverse
connectivity of SNPs, as well as the midbrain dopa-
minergic neurons (Fig. 1) [25–27]. Further dissecting
the local circuits and functional modalities of basal
ganglia neurons will likely redraw the wiring of
neural network that underlies the critical motor
control of vertebrates.
Opioid system in basal ganglia
High levels of endogenous opioid peptides and opioid
receptors are present in the basal ganglia [11]. Because
the wide distribution of opioid peptides and receptors in
the brain, it is difficult to determine whether the sources
of these peptides and receptors are inside or outside of
basal ganglia based on studying the protein expression
using western blot and immunostaining. By contrast,
the distribution of mRNAs determined by in situ
hybridization serves a better indicator to the patterns
of opioid peptide and receptor expression in basal
ganglia (Fig. 1). The endogenous opioid peptide
precursor PENK mRNAs are predominantly expressed
by the iSNPs, whereas PDYN mRNAs are more abun-
dant in the dSNPs [8, 28]. By contrast, the expression
of POMC mRNAs is restricted to hypothalamus. Penk
but not Pdyn mRNAs can also be detected in neur-
onal subpopulations in subthalamic nucleus and zona
incerta in rodent brains (Allen Brain Atlas), regions
Fig. 1 Endogenous opioid peptide and receptor gene expression and
alteration in basal ganglia under PD and LID conditions. A sketch of basal
ganglia local circuit map shows characteristic expression patterns of
endogenous opioid peptide and receptor genes in different sub-regions.
The inset highlights signature alterations of opioid peptide and receptor
expression in the dorsal striatum under PD and LID conditions. Oprm1: μ
opioid receptor; Oprd1: δ opioid receptor; Oprk1: κ opioid receptor; Penk:
preproenkephalin; Pdyn: pre-prodynorphin; GPe: globus pallidus external
segment; STh: subthalamic nucleus; SNc: substantia nigra pars compacta;
SNr: substantia nigra pars reticulata
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targeted for deep brain stimulation (DBS) in treatment of
PD and LID [29]. All three types of opioid receptors
express in the striatum, but display distinct distribution
patterns. The μ opioid receptors (OPRM1) are selectively
expressed by the SPNs located in the striosome compart-
ments in the rodent brains [30]. Correlatively, Oprm1
mRNAs also show a similar patchy distribution pattern in
rodent dorsal striatum (Allen). In addition, Oprm1
mRNAs appear at ventral striatum and GPe (Allen Brain
Atlas). δ-opioid receptors (Oprd1) mRNA-expressing cells
sparsely distribute at dorsal striatum, GPe, GPi, and SNr,
while more cells express Oprd1 in STh and ZI. κ-opioid
receptors (Oprk1) mRNAs are mainly detected in cells
distributed at ventral striatum and STh. Of interest, Oprk1
mRNAs are more enriched in SNc and ventral tegmental
area (VTA) compared to other opioid peptides and recep-
tors (Allen Brain Atlas). These distinct sub-regional locali-
zations of opioid peptides and receptors underlie the
diverse and complex functions of endogenous opioid
system in the basal ganglia [10].
Alterations of striatal opioid peptide and receptor
expression in LID
The expression levels of striatal PENK mRNAs correlate
with the severity of LID, suggesting a causal role of
increased opioid transmission in the development of
LID [17, 31]. However, the pathophysiological impact of
these alterations remains debatable [32]. Dopamine
depletion as occurred in the parkinsonian states leads to
increased expression of PENK mRNA in the iSPNs and
decreased expression of PDYN mRNAs in the dSPNs
(Fig. 1) [33, 34]. At the peak of LID, the expression of
PDYN mRNAs increases, while the expression of PENK
does not change (Fig. 1) [8, 33–35]. The expression of
PDYN mRNAs and peptides also elevates in STh
neurons in LID [34, 36]. However, such alterations of
opioid peptide expression may not cause LID, but rather
reflect an adaptive response compensating for the
prolonged L-DOPA treatment [37, 38].
Correlated with the alterations of opioid peptide
expression, opioid receptor levels also change in PD
and LID (Fig. 1) [39]. Dopamine depletion causes an
overall reduction of opioid receptor bindings, while
LID leads to a further reduction [34]. OPRM1 binding
levels are decreased in both the caudate and putamen
of PD patients under chronic L-DOPA administration
[40, 41]. OPRM1 levels are also suppressed in putamen
and GPi of monkey LID models [42]. On the other
hand, OPRM1 expression is increased in the premotor
and motor cortex of rat LID models [43]. Therefore, it
is important to investigate the differential alterations of
opioid peptide and receptor expression in different
brain regions in PD and LID.
Opioid signaling in the pathogenesis of LID
While OPRM1 cell surface presentation is decreased in
LID, OPRM1-mediated signal transduction is enhanced
in the striatum and GPi of LID models [44], suggesting
increased sensitivity of OPRM1 in the dyskinetic states.
Consistent with this notion, OPRM1 antagonists cypro-
dine and ADL5510 effectively reduce dyskinesia but
preserve the anti-parkinsonian efficacy of L-DOPA in
the monkey models [38, 45]. Moreover, a combination of
both OPRM1 and OPRD1 antagonists appear more
effective in reducing LID in animal models [46]. The
anti-LID efficacy of OPRM1 and OPRD1 antagonists
remains to be validated in PD patients, especially consid-
ering an earlier failed attempt with the non-selective opi-
oid receptor antagonist naloxone [47, 48]. In addition,
the diverse expression patterns of opioid receptors in
different brain regions and their differential responses in
the dyskinesia states may demand regional application of
either receptor subtype-selective agonists or antagonists
to effectively alleviate LID.
The underlying molecular mechanisms of LID remain
under intensive investigation [49]. Dysregulation of
cAMP and ERK signaling pathways has been reported in
PD and LID models [50]. Opioid receptors relay opioid
stimulation through Gi or Go-mediated inhibitory intra-
cellular signal transduction pathways [18], which may
suppress Golf or Gs-induced cAMP signaling in cells. For
example, pharmacological activation of OPRM1 and
OPRD1 blocks dopamine DRD1- or adenosine A2A-
receptor-induced activation of adenylyl cyclase and
reduces the production of cAMP in SPNs [51]. A reduc-
tion of cAMP levels may suppress protein kinase A
(PKA) activity and leads to an aberrant activation of
extracellular signal-regulated kinases (ERK1/2) in the
generation of LID [52, 53]. ERK activation may play a
causal role in the development of LID, as inhibition of
ERK activity alleviates dyskinesia phenotypes [54]. Opi-
oid receptor antagonists may achieve the anti-dyskinesia
effects through negatively regulating ERK1/2 signaling
[55]. Further studies, however, will be required to
improve current understanding of the complex inter-
plays between various signaling pathways critical in the
formation of abnormal synaptic transmission and plasti-
city in LID.
Conclusions
LID represents an erratic adaptive response to dopamine
denervation and repeated L-DOPA treatment. Although
selective opioid receptor antagonists can effectively alle-
viate LID in animal models, the underlying molecular,
cellular and circuit mechanisms remain to be character-
ized. The latest advance of next generation sequencing,
gene editing, opt genetics, and live imaging technologies
may greatly facilitate the inquiry of opioid signaling in
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the basal ganglia under normal and PD-like conditions.
Modulation of opioid receptor activity may provide an ef-
fective means to reduce LID and optimize the dopamine-
replacement therapy.
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